<DOC>
	<DOCNO>NCT00809094</DOCNO>
	<brief_summary>This Phase IIB proof-of-concept study would examine effect investigational product call N-acetylcysteine ( NAC ) basic process cause inflammation CF lung disease . We hope learn cause lung disease cystic fibrosis study characteristic inflammation lung patient CF .</brief_summary>
	<brief_title>NAC Phase IIB : A Multi-Center , Phase IIB , Randomized , Placebo-controlled , Double-Blind Study Of The Effects Of N-Acetylcysteine On Redox Changes Lung Inflammation In Cystic Fibrosis Patients</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>1 . Male female 7 year age old 2 . Diagnosis CF base upon follow criterion : 1 . One clinical feature characteristic CF AND ( b c ) 2 . Positive sweat test &gt; 60 mEq/L quantitative pilocarpine iontophoresis 3 . A genotype two identifiable mutation consistent CF 3 . Written informed consent ( assent applicable ) obtain subject subject 's legal representative 4 . Clinically stable evidence acute upper low respiratory tract infection within 4 week prior enrollment 5 . Stable mild moderately severe lung disease define FEV1 &gt; = 40 % &lt; = 85 % predict age base Wang ( male &lt; 18 year , females &lt; 16 year ) Hankinson ( male &gt; = 18 year , female &gt; = 16 year ) standardize equation 6 . Able tolerate sputum induction 3 % hypertonic saline expectorate 7 . Able perform repeatable , consistent effort pulmonary function test 8 . Weight &gt; = 25 kg time enrollment 9 . Females child bear potential must willing use birth control ( IUD , oral , transdermal , parenteral contraceptive ; abstinence ) 1 . Clinically significant liver enzyme ( AST , ALT GGT ) &gt; 2.5 time upper limit normal screen 2 . History ABPA , unless evidence stable IgE ( &lt; 5 % increase compare previous test ) 6 month prior enrollment 3 . Current history rheumatic collagen vascular disorder 4 . Use NSAIDS chronic therapy within 1 week prior enrollment 5 . Initiation chronic therapy ibuprofen , azithromycin , TOBI® Aztreonam within 6 week prior enrollment 6 . Consumption inhalation antioxidant ( include NAC , GSH , Immunocal , Nacystelyn , pentoxyfilline ) within 6 week prior enrollment 7 . Use oral IV corticosteroid within 4 week prior enrollment 8 . Use acetaminophen within 3 day prior enrollment 9 . Unable forego study : Vitamin E : 400 IU/day subject &lt; = 12 year age 800 IU/day subject &gt; 12 year age Vitamin C : 0.5 gm/day More two alcoholic drink per day 10 . Known hypersensitivity oral PharmaNAC® 11 . Current cigarette consumption 12 . Pregnant breastfeed 13 . Subject unlikely complete study determine Investigator 14 . Any condition Investigator believe would interfere intent study would make participation best interest subject 15 . Participation trial antiinflammatory therapeutic investigational drug within 6 week prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>